Research & development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91021D00021
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Pre-Solicitation · 75N91021R00007 · Posted Mar 23, 2020
- Last date to order 72% complete
- IDV ceiling
- $9,900,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development organization. The contract, with a ceiling value of $9,900,000, has an ultimate completion date of September 26, 2028.
The purpose of this IDC is to obtain research and development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. This includes implementing and validating analytical methodologies to quantify compounds in biological fluids and tissues, as well as conducting rapid pharmacokinetic assessments. The data generated under this contract will be used to support all phases of the drug development process, from lead selection and development to the support of early clinical trials. The contract was awarded without any small business set-asides, reflecting Sri International's status as a large, established research organization with extensive experience in delivering advanced R&D services to federal agencies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91021D00021?
75N91021D00021 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on September 27, 2021.
How much is contract 75N91021D00021 worth?
75N91021D00021's own ceiling is $9,900,000.
Who can order from contract 75N91021D00021?
75N91021D00021 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N91021D00021 competed?
The extent of competition for 75N91021D00021 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV